Wave Life Sciences reports Q4 2022 net loss $43.7M; cash runway into 2025 on $170M GSK upfront

Wave Life Sciences Ltd.

Q4 2022 net loss $43.7M vs $34.8M in Q4 2021; full-year 2022 net loss $161.8M vs $122.2M in 2021.
Cash and equivalents $88.5M at Dec 31, 2022; after period-end, received $170M upfront from GSK collaboration.
GSK collaboration includes up to $3.3B in potential milestones; Wave licensed WVE-006 for AATD to GSK.
WVE-006 on track for CTA submission in 2H 2023; Part B of WVE-N531 DMD study to begin in 2023 with dystrophin data in 2024.
Single-dose data from WVE-003 (HD) and WVE-004 (ALS/FTD) expected in 1H 2023; Takeda option for 50:50 co-development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Wave Life Sciences Ltd. reported financial results for the quarter and year ended December 31, 2022.

Period: the quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 22, 2023, Wave Life Sciences Ltd. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-23-076278

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.